PROGESTOGEN ADMINISTRATION IN PREGNANCY MAY PREVENT PRETERM DELIVERY
PROGESTOGEN ADMINISTRATION IN PREGNANCY MAY PREVENT PRETERM DELIVERY
复制标题
DOI：
10.1111/j.1471-0528.1990.tb01740.x
复制
发表时间：
1990-02-01
期刊：
影响因子：
--
通讯作者：
KEIRSE, MJNC
中科院分区：
文献类型：
--
作者：
KEIRSE, MJNC
两个最近发表的对妊娠中使用的多种促孕剂的对照试验的荟萃分析（Daya 1989; Goldstein等1989），促使了对涉及预防性使用单一药剂17 α-β的安慰剂对照试验的第三次荟萃分析。己酸羟孕酮在七份已发表的相关对照试验报告中，六份涉及被认为流产或早产风险高的女性。该分析不支持17 α-β的观点。己酸羟孕酮可以防止流产，但也表明它确实可以减少早产的发生。后一种效果反映在出生体重不足婴儿的比率下降，但围产期死亡率和发病率在统计上没有显著下降。本荟萃分析与前两个荟萃分析之间的差异说明了选择性亚组和综合汇总小型试验数据的问题。
Two recently published meta-analyses of controlled trials of a wide variety of progestational agents, used in pregnancy (Daya 1989; Goldstein et al. 1989), prompted this third meta-analysis of placebo-controlled trials involving the prophylactic use of a single agent, 17.alpha.-hydroxyprogesterone caproate. Of seven relevant published reports of controlled trials, six had involved women considered to be at high risk of miscarriage or preterm birth. This analysis provides no support for the view that 17.alpha.-hydroxyprogesterone caproate protects against miscarriage, but suggests that it does reduce the occurrence of preterm birth. The latter effect was reflected in a reduced rate of low birthweight babies, but not in a statistically significant reduction in perinatal mortality and morbidity. The difference between this meta-analysis and the two earlier meta-analyses illustrates the problems both of selective subgrouping and of comprehensive pooling of data from small trials.